替吉奥治疗卡培他滨耐药转移性乳腺癌的疗效分析
发布时间：2018-08-04 18:36
【摘要】：目的分析卡培他滨单药治疗耐药后的转移性乳腺癌患者接受替吉奥单药治疗的疗效及安全性。方法回顾性分析2011年11月—2015年5月宁波大学医学院附属医院肿瘤内科治疗的22例转移性乳腺癌患者的临床资料。22例患者接受卡培他滨单药治疗,在卡培他滨耐药后接受替吉奥单药治疗,直至疾病进展、不可耐受的毒副作用或患者拒绝治疗。按照实体瘤疗效评价标准(RECIST)进行替吉奥临床疗效评价,观察进展时间(TTP)及总生存期(OS),记录疼痛评分及CA153水平,根据美国国家癌症研究所发布的常见不良反应事件评价标准(CTCAE v4.02)进行毒副作用评价。结果 22例卡培他滨耐药的转移性乳腺癌患者接受替吉奥治疗后5例部分缓解,12例疾病稳定,5例疾病进展,客观有效率(ORR)为22.7%(5/22),临床获益率(CBR)为77.3%(17/22);中位TTP为113 d(22~218 d),中位OS为20.2个月(3.8~38.2个月)。替吉奥治疗前有15例患者有疼痛表现,未经提高止痛药物剂量,治疗后10例患者疼痛减轻。开始替吉奥治疗时CA153水平与治疗过程中最低CA153水平比较,差异有统计学意义[(174.8±67.4)U/ml与(102.8±69.7)U/ml,t=4.174,P=0.001]。替吉奥治疗的毒副作用均可耐受,主要毒副作用有厌食[59.1%(13/22)]、恶心[50.0%(11/22)]、乏力[45.5%(10/22)]、中性粒细胞计数减少[45.5%(10/22)]、贫血[40.9%(9/22)]、腹泻[36.4%(8/22)]、手足综合征[27.3%(6/22)]、转氨酶升高[22.7%(5/22)]及呕吐[18.2%(4/22)]等。毒副作用多为Ⅰ~Ⅱ级,仅3例发生Ⅲ级毒副作用。结论替吉奥单药对于卡培他滨单药耐药的转移性乳腺癌有一定的疗效,而且耐受性良好。因此,对于使用卡培他滨单药治疗后耐药的转移性乳腺癌可考虑选用替吉奥单药治疗。
[Abstract]:Objective to evaluate the efficacy and safety of capecitabine in the treatment of metastatic breast cancer after drug resistance. Methods the clinical data of 22 patients with metastatic breast cancer treated by Department of Oncology, affiliated Hospital of Ningbo University Medical College from November 2011 to May 2015 were analyzed retrospectively. 22 patients were treated with capecitabine alone. After capecitabine resistance, teguir alone is given until the disease progresses, intolerable side effects or patients refuse treatment. According to the criteria for evaluating the curative effect of solid tumor, (RECIST) was used to evaluate the clinical efficacy of teguir. The progressive time (TTP), total survival time (OS),) and total survival time (OS),) were observed to record pain score and CA153 level. The toxicity and side effects were evaluated according to CTCAE v4.02, published by the National Cancer Institute. Results 22 patients with metastatic breast cancer who were resistant to capecitabine were treated with teguir in 5 patients with partial remission 12 patients with stable disease and 5 patients with disease progression. The objective effective rate (ORR) was 22.7% (5 / 22), the clinical benefit rate (CBR) was 77.3% (17 / 22) and the median TTP was 113d (median OS = 20.2 months (3.8 ~ 38.2 months) for 22218 d),). There were 15 patients with pain symptoms before tigor treatment and 10 patients with pain relief after treatment without increasing the dose of analgesic drugs. There was a significant difference between the level of CA153 and the lowest level of CA153 (174.8 卤67.4) U/ml and (102.8 卤69.7) U / ml ~ (-1) U/ml at the beginning of tiguir treatment [(174.8 卤67.4) U/ml and (102.8 卤69.7) U / ml ~ (4.174) U/ml]. The main side effects of tigor were anorexia [59.1% (13 / 22)], nausea [50.0% (11 / 22)], fatigue [45.5% (10 / 22)], neutrophil count decrease [45.5% (10 / 22)], anemia [40.9% (9 / 22)], diarrhea [36.4% (8 / 22)], hand and foot syndrome (27.3% (6 / 22)], elevated transaminase [22.7% (5r22)] and vomiting (418.22%). Most of the toxic side effects were grade 鈪，
本文编号：2164757
[Abstract]:Objective to evaluate the efficacy and safety of capecitabine in the treatment of metastatic breast cancer after drug resistance. Methods the clinical data of 22 patients with metastatic breast cancer treated by Department of Oncology, affiliated Hospital of Ningbo University Medical College from November 2011 to May 2015 were analyzed retrospectively. 22 patients were treated with capecitabine alone. After capecitabine resistance, teguir alone is given until the disease progresses, intolerable side effects or patients refuse treatment. According to the criteria for evaluating the curative effect of solid tumor, (RECIST) was used to evaluate the clinical efficacy of teguir. The progressive time (TTP), total survival time (OS),) and total survival time (OS),) were observed to record pain score and CA153 level. The toxicity and side effects were evaluated according to CTCAE v4.02, published by the National Cancer Institute. Results 22 patients with metastatic breast cancer who were resistant to capecitabine were treated with teguir in 5 patients with partial remission 12 patients with stable disease and 5 patients with disease progression. The objective effective rate (ORR) was 22.7% (5 / 22), the clinical benefit rate (CBR) was 77.3% (17 / 22) and the median TTP was 113d (median OS = 20.2 months (3.8 ~ 38.2 months) for 22218 d),). There were 15 patients with pain symptoms before tigor treatment and 10 patients with pain relief after treatment without increasing the dose of analgesic drugs. There was a significant difference between the level of CA153 and the lowest level of CA153 (174.8 卤67.4) U/ml and (102.8 卤69.7) U / ml ~ (-1) U/ml at the beginning of tiguir treatment [(174.8 卤67.4) U/ml and (102.8 卤69.7) U / ml ~ (4.174) U/ml]. The main side effects of tigor were anorexia [59.1% (13 / 22)], nausea [50.0% (11 / 22)], fatigue [45.5% (10 / 22)], neutrophil count decrease [45.5% (10 / 22)], anemia [40.9% (9 / 22)], diarrhea [36.4% (8 / 22)], hand and foot syndrome (27.3% (6 / 22)], elevated transaminase [22.7% (5r22)] and vomiting (418.22%). Most of the toxic side effects were grade 鈪，
本文编号：2164757
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2164757.html
